US Food and Drug Administration (FDA) recently announced that Novo Nordisk's blockbuster drugs, Ozempic and Wegovy, are no ...

Compounders have filed a lawsuit against the FDA challenging its decision to remove Novo Nordisk's Wegovy and Ozempic from the shortage list. The lawsuit claims the FDA's actions are arbitrary, ...

Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...

Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...

The shortages were declared in August 2022. Meanwhile, Axios reports on how makers of copycat weight loss drugs are preparing for a crackdown. In medical tech and pharma news: a pacemaker recall, the ...

This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.

With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed ...

US FDA declares Wegovy & Ozempic shortage is over and that Novo Nordisk is fully meeting or exceeding nationwide demand for all doses: Plainsboro, New Jersey Monday, February 24, ...

The FDA says the nationwide shortage for Ozempic and Wegovy is over, but as CBS News New York's Ali Bauman explains, that ...